Shots: Shots:

• The P-III ADVANCE study involves assessing of Otezla (apremilast- 30mg- bid for 16wks.) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis. Later- patients will receive Otezla during an open-label extension phase @32wks.
• The P-III ADVANCE study results: @16wks.- improvement in its 1EPs of sPGA score; achieve 2EPs i.e- 75% improvement in BSA- change in PASI score  
• Otezla is a selective PDE4 inhibitor- inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. plaque psoriasis who are candidates for phototherapy or systemic therapy- for active PsA and for with oral ulcers associated with Behçet's Disease

Click here ­to­ read full press release/ article | Ref: Amgen | Image: StraitTimes

Related News: Amgen Receives Health Canada’s Marketing Authorization Transfer of Otezla for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis